Quote & Headlines
Market Currents
StockTalk
Today
5d
1m
3m
1y
5y
10y
52wk high:
52wk low:
EPS:
PE:
Div Rate:
Yield:
Market Cap:
Volume:
14,273 people get ABT articles and Market Currents by email alert.
Get email alerts on ABT »
HEADLINES:
ALL
|
PRO
|
FOCUS
|
RELATED
|
TRANSCRIPTS
|
NEWS & PR
-
-
-
-
-
-
-
-
At These Levels, Covidien Has Room To RunStephen Barnes • Tue, Apr 30 -
-
-
-
-
-
-
-
-
-
-
To learn more about Seeking Alpha Pro, click here.
-
-
-
-
-
-
-
-
-
-
-
Abbott Hopes Mitral Repair Will Be The New TAVIEP Vantage • Wed, Feb 27 -
-
-
-
-
-
-
-
Abbott Earnings Preview: What We Are WatchingTrefis • Tue, Jan 22
-
-
Abbott Laboratories' Management Presents HCV Program Update (Transcript)Mon, Nov 12, 2012
-
Abbott Laboratories Q1 2010 Earnings Call TranscriptWed, Apr 21, 2010
-
Abbott Laboratories Q4 2009 Earnings Call TranscriptWed, Jan 27, 2010
-
Abbott Laboratories, Q3 2009 Earnings Call TranscriptWed, Oct 14, 2009
-
Abbott Laboratories, Q2 2009 Earnings Call TranscriptWed, Jul 15, 2009 • 1 Comment
-
Abbott Laboratories Q1 2009 Earnings Call TranscriptFri, Apr 17, 2009
-
Abbott Laboratories Q4 2008 Earnings Call TranscriptWed, Jan 21, 2009
-
Abbott Laboratories Q3 2008 Earnings Call TranscriptWed, Oct 15, 2008
-
at CNBC.com (Fri, 6:29PM)
-
at CNBC.com (Fri, 6:02PM)
-
at CNBC.com (May 13, 2013)
-
at MarketWatch.com (Apr 30, 2013)
-
at CNBC.com (Apr 29, 2013)
-
at CNBC.com (Apr 22, 2013)
-
at MarketWatch.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 17, 2013)
-
at CNBC.com (Apr 17, 2013)
-
at MarketWatch.com (Apr 16, 2013)
-
at CNBC.com (Apr 14, 2013)
-
at CNBC.com (Apr 3, 2013)
-
at CNBC.com (Apr 2, 2013)
-
at MarketWatch.com (Mar 22, 2013)
-
at CNBC.com (Mar 20, 2013)
-
at CNBC.com (Mar 11, 2013)
-
at CNBC.com (Feb 14, 2013)
-
at MarketWatch.com (Jan 30, 2013)
-
at MarketWatch.com (Jan 23, 2013)
ABT vs. ETF Alternatives
Company Description
Abbott Laboratories is an Illinois corporation, incorporated in 1900. Abbott's* principal business is the discovery, development, manufacture, and sale of a broad and diversified line of health care products.
Abbott has four reportable revenue segments: Pharmaceutical Products, Diagnostic... More
- All
- | Earnings
- | Dividends
- | M&A
- | On the move
- Monday, May 6, 1:36 PM Merck (MRK -1.3%) gets no love today from the FDA's approval of Liptruxet late Friday, as the stock is likely dragged down with the rest of the big pharma names on the back of a CNBC report that criticizes their earnings so far. The article points to the fact that pharmaceutical companies have seen a 4.7% contraction in earnings, and a 3.2% drop in revenue this quarter. Why? Morningstar's Damien Cover says there are two primary reasons: FX impact, especially from the yen, and intensified generic competition from patent losses. Comment! [Healthcare, On the Move]
- Wednesday, April 10, 10:31 AM BG Medicine (BGMD +3.6%) trades up after announcing earlier that partner Abbott (ABT +0.2%) has obtained a CE Mark for its Galectin-3 assay run on the Architect immunochemistry platform. The Galectin-3 assay is an indicator that assesses the risk for readmission in heart failure. BGMD is partnering with four diagnostic instrument manufacturers to commercialize automated versions of the test, making it available in several European countries, pending country registration. Comment! [Healthcare, On the Move, Global & FX]
- Friday, February 15, 10:43 AM Shares of Abbott Labs (ABT +1%) tick higher after being initiated by analysts at Stifel Nicolaus with a Buy and a price target of $40 per share, noting that the drug giant is a solid performer that delivers reliable and consistent earnings growth. Comment! [Healthcare, On the Move]
- Wednesday, January 23, 7:51 AM Abbott Labs (ABT): Q4 EPS of $1.51 beats by $0.01. Revenue of $10.84B beats by $0.26B. Shares +3% premarket. (PR) 1 Comment [Earnings, Breaking News, Healthcare, On the Move]
- Thursday, January 3, 8:28 AM BG Medicine (BGMD) rockets 24% after saying it has received the EU's CE mark for the first automated version of the company's Galectin-3 blood test for improving the management of heart conditions. BG is working with four partners to commercialize the test, including Abbott Labs (ABT) and Siemens (SI). The EU approval comes just a week after SA author Robert Fabian called BG Medicine a "hidden gem." (PR) Comment! [Healthcare, On the Move]
-
Wednesday, January 2, 12:45 PM
Midday top 10 gainers: ZIP +48%. BIOF +28%. STXS +25%. GIGA +21%. FORD +19%. IQNT +20%. EGLE +18%. OTT +18%. GEVO +17%. APAGF +17%.
Midday top 10 Losers: ABT -51%. SKUL -14%. DOLE -13%. TRIT -12%. ATAI -12%. HMNY -9%. CHRM -9%. NTLS -9%. VSCI -8%. MR -8%. 2 Comments [On the Move] - Thursday, October 18, 2012, 9:31 AM Reata Pharmaceuticals has told Abbott Labs (ABT -4.4%) that it's discontinuing Phase 3 trials of bardoxolone methyl in patients with advanced chronic kidney disease and Type 2 diabetes following "excess serious adverse events and mortality." Reata and Abbott, which holds the rights to the drug outside the U.S., will examine the data to see whether it can still be developed. (8-K) Comment! [On the Move, Healthcare]
- Tuesday, October 16, 2012, 12:36 PM Achillion (ACHN +4.6%) gains on a price target increase to $17 from $12 at Deutsche Bank. The firm says liver abstracts from Bristol-Myers (BMY +0.6%) and Abbott (ABT +0.1%) bode well for the future success of ACHN's two drug combo regimens for the treatment of hepatitus C virus. The firm made similar comments yesterday about Gilead (GILD +1.6%). Comment! [Healthcare, On the Move]
- Monday, October 15, 2012, 1:50 PM Gilead (GILD -0.9%) slips a bit today after Bristol-Myers (BMY +3.2%) and Abbott (ABT +3.7%) both reported favorable study results for their HCV drugs (I,II). Deutsche Bank defends the stock , saying the results of these studies show that utilizing different drug combinations yields more effective HCV treatments, and that this data actually bodes well for GILD's 7977-based class combos, for which it expects the drug developer to yield similar results. Comment! [Healthcare, On the Move]
- Monday, October 15, 2012, 12:58 PM Abbott (ABT +3.4%) moves up after initial results from its "Aviator" Phase 2b study of its interferon-free, investigational regimen for the treatment of hepatitis C indicated that 99% of the "treatment naive" HCV patients - those who had never been previously treated for the virus - showed a sustained virological response. Additionally, 93% of patients in the study who had previously been unsuccessfully treated for HCV also showed sustained virological response. 2 Comments [Healthcare, On the Move]
- Monday, July 23, 2012, 3:08 PM Akorn (AKRX -8%) gets pummeled on a Deutsche downgrade to Hold, citing its high valuation, a lack of exclusivity for a generic version of Abbott's (ABT -0.6%) Prometrium, and a weaker than expected Vancomycin launch. The firm also cuts its price target to $14 from $15. 1 Comment [Healthcare, On the Move]
- Thursday, June 28, 2012, 10:53 AM Pharmaceutical stocks are down following the Supreme Court healthcare opinion, although not dramatically: AZN -0.4%, GSK -1.6%, SNY -0.8%, PFE -0.8%, ABT -0.8%, MRK -0.7%, LLY -1%, WPI -0.9%, NVS -0.7%, JNJ -0.4%. iShares Dow Jones US Healthcare ETF (IYH) -0.95%, the Health Care SPDR (XLV) is -1.3%. 2 Comments [Healthcare, On the Move]
- Wednesday, April 4, 2012, 12:48 PM Shares of Idenix Pharmaceuticals (IDIX -12.2%) sink after Abbott Laboratories (ABT +0.6%) releases positive results from studies of its experimental hepatitis C treatment. Other Hep-C companies vying for a piece of the rapidly-growing multi-billion dollar market: Gilead Sciences (GILD -2.2%), Vertex Pharmaceuticals (VRTX -1.2%), Bristol-Myers Squibb (BMY -0.5%), BioCryst Pharmaceuticals (BCRX -3.4%). 1 Comment [On the Move, Healthcare]
- Monday, March 19, 2012, 3:14 PM Abbott Labs (ABT +1.4%) hits a three-year high as Deutsche Bank hikes its rating to Buy, arguing shares should climb ahead of the planned split of ABT’s drug unit from the rest of the company. Pharma could be worth $36/share by year-end 2012, the firm says, while the faster-growing medical products business could carry a value of $31/share. Comment! [Healthcare, On the Move]
- Thursday, March 8, 2012, 1:30 PM Abbott Laboratories (ABT +2.4%) trades higher after receiving FDA clearance to sell its FreeStyle InsuLinx system for monitoring blood glucose levels. InsuLinx, which is already available for sale in Canada and several European countries, is the first glucose monitoring system from Abbott to feature a touchscreen and automated logbook. Comment! [Healthcare, On the Move]
- Wednesday, January 18, 2012, 10:11 AM Wedbush sets a new price target for Idenix Pharmaceuticals (IDIX +4.3%) of $24 on renewed speculation that a Big Pharma player may take an interest in buying the company. Potential suitors: MRK, JNJ, ABT. Comment! [On the Move, Healthcare]
-
- View all 0 replies
-
- View all 0 replies
-
Derek A. Barrett
Sold $ABBV after reaching 50% Graham profit target. Still holding $ABT in 401k. I am seriously running out of value ideas ! - View all 15 replies
-
Derek A. Barrett: Thanks for the info guys! Bret Jensen also did an article on the Street when $CBI was about 10% lower, so looks like a solid pickup.
-
-
- View all 0 replies
-
- View all 0 replies
-
- View all 0 replies
-
- View all 1 replies
-
-
- View all 4 replies
-
Minutemen: INTC up over $22 on a broad market sell off. Gotta like that. Investors starting to see INTC's value.
-
-
- View all 0 replies
-
- View all 0 replies
LATEST REPLIES
-
Derek A. Barrett
Sold $ABBV after reaching 50% Graham profit target. Still holding $ABT in 401k. I am seriously running out of value ideas ! - View all 15 replies
-
Derek A. Barrett: Thanks for the info guys! Bret Jensen also did an article on the Street when $CBI was about 10% lower, so looks like a solid pickup.
-
-
- View all 13 replies
-
-
Derek A. Barrett: Not sure if anyone is still following this thread, but $ABBV has hit my 50% Graham profit target so I will be selling. Great job $ABBV!
-
- View all 1 replies
-
-
- View all 4 replies
-
Minutemen: INTC up over $22 on a broad market sell off. Gotta like that. Investors starting to see INTC's value.
-
-
- View all 1 replies
-
Minutemen: Yeah, RSI is in oversold territory. I'm long ABT so will just ride it out.
-
- View all 3 replies
-
SKS1586: Thanks my friend. I am a Trader. I increase & reduce position frequently. I sell with small profit to create CASH for other opportunities.
-
SKS1586: Rubenov: You are correct. Correction may happen anytime. I work predominantly with Turnarounds + Scale in slowly & remove profit every week.
-
- View all 2 replies
-
-
SKS1586: joe kelly - I reduce or remove my positions for creation of CASH. Therefore I leave trades with much less profit than most Investors/Traders
-
- View all 5 replies
-
Brennan Basnicki: Yah looks like it. I was really bullish, but a few key trend lines probably will be taken out. Will be seeing how $ANR and $WLT react
-
-
- View all 3 replies
-
Brennan Basnicki: No, haven't tried any shorts for a while. Any time I have they have been short term, with recent one's being losers unfortunately!
-
Brennan Basnicki: The chart is actually pretty bullish right now, however I am bearish on fundamentals. In any case, I don't expect to trade it anytime soon
-
- View all 7 replies
-
Minutemen: Yes. See the following article (in which the author proposes selling ABBV and buying more ABT): http://on-msn.com/ZBOUmr
-
-
Ryan Mallory
16 Defensive Stock Plays to Weather Market Uncertainty http://bit.ly/RVR8Ko AAPL ABT AMZN AZN MRK NVS PEP to name a few of them - View all 1 replies
-
driftking27: How do you see the strong CHf affecting there growth. I think that could be one hurdle that could hurt there sales. Plus NVS drops more...
-
- View all 3 replies
-
-
-
Brodidliy1
I've done pretty well with Abbot Labs (ABT). Think I should take some profits or keep my shares ahead of the company split? - View all 2 replies
-
-
Brodidliy1: Still reading through the quarterly report, but I think I like the long term prospects of the abt post split. Had a great run though
-
- View all 3 replies
-
-
-
- View all 3 replies
-
-
